Xenon Pharmaceuticals sinks as psychiatry trial pause overshadows epilepsy NDA filing

Xenon Pharmaceuticals (XENE) is down 29.1% today. Here is some analysis on what might have caused this price movement.

Analysis: The sharp selloff appears tied to Xenon’s decision to temporarily pause enrollment of new patients in its ongoing major depressive disorder and bipolar depression studies after reviewing neuropsychiatric adverse events. While the company also announced an FDA new drug application submission for azetukalner in focal seizures, investors seem to be focusing on the added safety uncertainty and the possibility that psychiatry expansion could be delayed or worth less than previously expected.

Details:

Xenon said it voluntarily paused new patient enrollment in ongoing psychiatry studies as a precaution after analyzing neuropsychiatric adverse events, while keeping currently enrolled patients on study.

The company said those events had not been seen in the earlier Phase 2 X-NOVA study in major depressive disorder, which likely raised fresh concern about the drug’s risk profile in psychiatry.

X-NOVA2 enrollment was completed at about 360 patients, roughly 80% of the original target, and topline data are now expected in the first quarter of 2027.

Analyst commentary published after the update indicated some firms cut price targets and removed part of their commercial assumptions for depression and bipolar depression, reinforcing the negative reaction.

Sources:

Xenon Pharmaceuticals, Yahoo Finance, Fierce Biotech

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$XENE Insider Trading Activity

$XENE insiders have traded $XENE stock on the open market 5 times in the past 6 months. Of those trades, 0 have been purchases and 5 have been sales.

Here’s a breakdown of recent trading of $XENE stock by insiders over the last 6 months:

STEVEN GANNON sold 10,000 shares for an estimated $640,550
CHRISTOPHER JOHN KENNEY (Chief Medical Officer) has made 0 purchases and 2 sales selling 7,068 shares for an estimated $425,828.
GARY PATOU sold 1,322 shares for an estimated $70,251
GILLIAN CANNON sold 1,190 shares for an estimated $63,236

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$XENE Hedge Fund Activity

We have seen 173 institutional investors add shares of $XENE stock to their portfolio, and 129 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

WELLINGTON MANAGEMENT GROUP LLP removed 3,404,149 shares (-70.5%) from their portfolio in Q2 2026, for an estimated $205,474,433
JPMORGAN CHASE & CO added 2,617,360 shares (+inf%) to their portfolio in Q2 2026, for an estimated $157,983,849
T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 2,076,034 shares (+2243.2%) to their portfolio in Q2 2026, for an estimated $125,309,412
PRICE T ROWE ASSOCIATES INC /MD/ added 1,918,628 shares (+144.3%) to their portfolio in Q2 2026, for an estimated $115,808,386
BLACKROCK, INC. added 1,882,364 shares (+33.4%) to their portfolio in Q2 2026, for an estimated $113,619,491
HOLOCENE ADVISORS, LP removed 1,518,686 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $91,667,886
CITADEL ADVISORS LLC added 1,331,777 shares (+100.8%) to their portfolio in Q1 2026, for an estimated $77,442,832

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$XENE Analyst Ratings

Wall Street analysts have issued reports on $XENE in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Needham issued a "Buy" rating on 05/08/2026

To track analyst ratings and price targets for $XENE, check out Quiver Quantitative's $XENE forecast page.

$XENE Price Targets

Multiple analysts have issued price targets for $XENE recently. We have seen 3 analysts offer price targets for $XENE in the last 6 months, with a median target of $82.0.

Here are some recent targets:

Tessa Romero from JP Morgan set a target price of $82.0 on 05/27/2026
Serge Belanger from Needham set a target price of $78.0 on 05/08/2026
Brian Abrahams from RBC Capital set a target price of $82.0 on 05/08/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.